Comparative Efficacy of Drugs for Pediatric NAFLD from a Bayesian Network Meta-Analysis

19 randomized controlled trials involving 1,582 pediatric NAFLD patients form the basis of this analysis. The dataset, published by Ming-Lu Wang on figshare, compares the efficacy of drugs targeting energy, inflammation, fibrosis, and gut microbiota pathways. It includes primary outcomes on hepatic steatosis improvement and secondary outcomes on liver enzymes, lipids, and metabolic parameters.

Use Cases

• Ranking drug efficacy for improving hepatic steatosis based on relative risk and credible intervals
• Identifying optimal drug classes for secondary outcomes like ALT reduction based on SUCRA scores
• Informing combination therapy selection for pediatric NAFLD based on mechanistic pathway comparisons

Strengths

• Includes data from 19 randomized controlled trials, a standard for clinical evidence
• Analyzes outcomes for 1,582 pediatric patients, providing a specific patient population focus
• Employs Bayesian network meta-analysis, a sophisticated statistical method for comparative efficacy

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Aggregated from randomized controlled trials identified via systematic review (PROSPERO CRD42023417431).

Freshness

Last updated 2026-05-25 04:33:08; freshness should be verified